The Gross Margin of Acceleron Pharma Inc (XLRN) is
100.00%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2020-12-31 |
100.00%
|
| 2019-12-31 |
100.00%
|
| 2018-12-31 |
98.15%
|
| Ticker |
Name |
Value |
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
BPMC
|
Blueprint Medicines Corp
|
96.04%
|
|
FGEN
|
FibroGen Inc
|
47.47%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
7775.20%
|
|
TGTX
|
TG Therapeutics, Inc.
|
83.66%
|
|
UTHR
|
United Therapeutics Corporation
|
87.92%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
BHVN
|
Biohaven Ltd.
|
72.18%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
69.33%
|
|
VIE
|
Viela Bio Inc
|
82.49%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
78.92%
|
|
FATE
|
Fate Therapeutics Inc
|
7775.20%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
34.28%
|
|
KOD
|
Kodiak Sciences Inc.
|
7775.20%
|
|
LEGN
|
Legend Biotech Corporation
|
60.34%
|
|
MRTX
|
Mirati Therapeutics Inc
|
95.18%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
7775.20%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
93.45%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
9.32%
|
|
ASND
|
Ascendis Pharma A/S
|
86.82%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
98.31%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
89.81%
|
|
CCXI
|
Churchill Capital Corp XI
|
99.06%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
83.62%
|
|
RVMD
|
Revolution Medicines, Inc.
|
7775.20%
|
|
SANA
|
Sana Biotechnology, Inc.
|
7775.20%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
7775.20%
|
|
CRSP
|
CRISPR Therapeutics AG
|
7775.20%
|